New Zealand markets close in 5 hours 17 minutes

Senti Biosciences, Inc. (SNTI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4000-0.0112 (-2.72%)
At close: 04:00PM EST
0.4000 0.00 (0.00%)
After hours: 05:07PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.4112
Open0.3990
Bid0.3978 x 800
Ask0.4199 x 1000
Day's range0.3978 - 0.4100
52-week range0.2700 - 1.6700
Volume149,212
Avg. volume781,358
Market cap17.818M
Beta (5Y monthly)3.08
PE ratio (TTM)N/A
EPS (TTM)-1.9600
Earnings date04 Mar 2024 - 08 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.00
  • GlobeNewswire

    Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

    – Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% reduction in workforce, expected to extend cash runway into 1Q 2025 – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology

  • Zacks

    Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

    The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

  • GlobeNewswire

    Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

    – First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell therapy using Logic Gated Gene Circuits to selectively target cancer cells while sparing healthy bone marrow cells – SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical stage biote